ClinicalTrials.gg
Not yet recruitingNCT06004843EROPUpdated Aug 28, 2023

The Effects of Remimazolam on the Incidence of Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients

An interventional study of remimazolam and Propofol in Hypoxia, Hysteroscopy and Overweight or Obesity, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-08-28.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypoxia by RenJi Hospital — 5 open to participants now, 5 under way, none of them phase 3. Hypoxia · RenJi Hospital.

Planned enrollment
9th of 14
600 · median 980
Started
2023
with 1 other
No phase
14 of 14
5 open now
Registered
12th of 14
by date

Among the 14 studies in Hypoxia by RenJi Hospital, this one is the 9th largest by planned enrollment, is one of 2 that started in 2023, is one of 14 with no phase, and was the 12th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

5 of the 14 studies in Hypoxia by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 20 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypoxia by RenJi Hospital, or all of them as a file.
02

Study summary

Hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. In sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. The present study is a single-center, randomized, single-blind, controlled clinical trial. Overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with ASA grade I or II, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. Sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of hypoxia during surgery between the two groups of patients.

03

Conditions studied

  • Hypoxia
  • Hysteroscopy
  • Overweight or Obesity

Keywords

  • hypoxia
  • hysteroscopy
  • Overweight or Obesity
  • remimazolam
  • propofol
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 20 and 50 years.
  2. Patients undergoing sedated hysteroscopy for assisted reproduction.
  3. I-II.
  4. ≥ 23 kg/㎡.
  5. Patients who have signed an form.

Exclusion criteria

Exclusion Criteria:

  1. SpO2 \< 95% in patients inhaling air upon entering the room.
  2. Diagnosed with (COPD) or currently suffering from other acute and chronic lung diseases requiring long-term or intermittent oxygen therapy.
  3. Patients with a history of mental and neurological disorders: such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, etc.
  4. Patients with severe liver dysfunction.
  5. Patients with severe renal insufficiency (requiring dialysis before surgery).
  6. Severe heart failure (METS \< 4).
  7. History of drug abuse and/or alcohol abuse within the 2 years preceding the screening period (consuming more than three times the standard alcoholic beverages daily, approximately 10g of alcohol, or equivalent to 50g of Chinese alcohol).
  8. Allergies or to benzodiazepines, flumazenil, opiates and their rescue medications, propofol, eggs, or soy products.
  9. Breastfeeding women.
  10. Patients whom investigator believe are unsuitable for participating in this trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Remimazolam

    In this group, participants are sedated with remimazolam and remifentanil.

    Drug: remimazolam

  • Active comparator
    propofol

    In this group, participants are sedated with propofol and remifentanil.

    Drug: Propofol

Interventions

  • in this group,patients are treated with remimazolam and remifentanil for reduced sedation.

  • in this group,patients are treated with propofol and remifentanil for reduced sedation.

06

What researchers measure

Primary outcomes

  1. The incidence of hypoxia

    75%≤ SpO2% ≤89% for\<60s

    Time frame: Participants will be followed for the duration of their hospital stay, with an expected average of about 2 hours.

Secondary outcomes

  1. The incidence of sub-clinical respiratory depression

    90%≤ SpO2\<95%

    Time frame: Participants will be followed for the duration of their hospital stay, with an expected average of about 2 hours.

  2. The incidence of severe hypoxia

    SpO2\<75% or 75%≤ SpO2≤89% for≥60s

    Time frame: Participants will be followed for the duration of their hospital stay, with an expected average of about 2 hours.

  3. The incidence of other adverse events

    Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force

    Time frame: Participants will be followed for the duration of their hospital stay, with an expected average of about 2 hours.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Feb 2026, 30 months later.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 30 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 22, 2023
StartEst.
Aug 2023
Primary completionEst.
Feb 2026
CompletionEst.
Apr 2026
Last update
Aug 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06004843
Lead sponsor
RenJi Hospital
Responsible party
diansan su (Vice chair of the department of anesthesiology, RenJi Hospital) — Principal investigator
First posted
Aug 22, 2023
Start date
Aug 2023 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Aug 28, 2023

Study contacts

diansan su, Dr
Contact
diansansu@yahoo.com
+862168383702
yanhua he, B.S
Contact
2339570124@qq.com
+862168383702

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion